This study is testing a new medicine called Rezafungin to see if it's safe and effective in stopping serious fungal infections. Fungal infections are caused by different types of fungi, which are a kind of germ. The study compares Rezafungin to the usual medicines given to people receiving a special type of treatment called an allogeneic blood and marrow transplantation, where healthy blood-making cells are given to a person to help them make new healthy cells. This is a Phase 3 study, meaning it's in the later stages of testing.

• Study Length: Participation in the study includes follow-ups for 90 days after the blood and marrow transplant.
• Visits Needed: Regular check-ups are required to monitor safety and effectiveness.
• Eligibility: You must be 18 or older, have certain blood-related diseases, and meet specific health criteria to participate.

The study excludes people with certain health issues, such as serious heart or lung problems, or those who have a history of certain fungal diseases. It's important to talk with your doctor to see if joining this study is a good choice for you.